Search Results for: AR

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
EGFR epidermal growth factor receptor
  • Signaling by ERBB2
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Signaling by ERBB4
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • PLCG1 events in ERBB2 signaling
  • PIP3 activates AKT signaling
  • Signaling by EGFR
  • GRB2 events in EGFR signaling
  • GAB1 signalosome
  • SHC1 events in EGFR signaling
  • EGFR downregulation
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • EGFR interacts with phospholipase C-gamma
  • EGFR Transactivation by Gastrin
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Signal transduction by L1
  • Constitutive Signaling by EGFRvIII
  • Inhibition of Signaling by Overexpressed EGFR
  • RAF/MAP kinase cascade
  • ERBB2 Regulates Cell Motility
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • ERBB2 Activates PTK6 Signaling
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis
  • PTK6 promotes HIF1A stabilization
  • Downregulation of ERBB2 signaling
  • TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
  • Extra-nuclear estrogen signaling
  • NOTCH3 Activation and Transmission of Signal to the Nucleus
  • HCMV Early Events
  • Estrogen-dependent nuclear events downstream of ESR-membrane signaling
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Cetuximab
  • Lidocaine
  • Gefitinib
  • Erlotinib
  • Lapatinib
  • Panitumumab
  • Alvocidib
  • IGN311
  • Matuzumab
  • Vandetanib
  • Rindopepimut
  • Canertinib
  • Pelitinib
  • Varlitinib
  • AV-412
  • S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
  • PD-168393
  • Afatinib
  • Osimertinib
  • Necitumumab
  • Foreskin keratinocyte (neonatal)
  • Depatuxizumab mafodotin
  • Icotinib
  • Neratinib
  • Dacomitinib
  • Fostamatinib
  • Zalutumumab
  • Brigatinib
  • Olmutinib
  • Zanubrutinib
  • Abivertinib
  • Choriocarcinoma
  • Gastric cancer
  • Bladder cancer
  • Oral cancer
  • Glioma
  • Laryngeal cancer
  • Cervical cancer
  • Esophageal cancer
PTEN phosphatase and tensin homolog
  • Synthesis of PIPs at the plasma membrane
  • Synthesis of IP3 and IP4 in the cytosol
  • Negative regulation of the PI3K/AKT network
  • Downstream TCR signaling
  • TP53 Regulates Metabolic Genes
  • PTEN Loss of Function in Cancer
  • Ub-specific processing proteases
  • Ovarian tumor domain proteases
  • Regulation of PTEN mRNA translation
  • Regulation of PTEN localization
  • Regulation of PTEN stability and activity
  • Transcriptional Regulation by MECP2
  • Phosphatidylethanolamine
  • Vulvar cancer
  • Prostate cancer
  • Endometrial Cancer
  • Glioma
  • Small cell lung cancer
  • Breast cancer
  • Hepatocellular carcinoma
  • Malignant melanoma
RB1 RB transcriptional corepressor 1
  • Inhibition of replication initiation of damaged DNA by RB1/E2F1
  • Inhibition of replication initiation of damaged DNA by RB1/E2F1
  • APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
  • Condensation of Prophase Chromosomes
  • Formation of Senescence-Associated Heterochromatin Foci (SAHF)
  • Oncogene Induced Senescence
  • Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes
  • Cyclin E associated events during G1/S transition
  • Cyclin D associated events in G1
  • Cyclin A:Cdk2-associated events at S phase entry
  • RUNX2 regulates osteoblast differentiation
  • Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)
  • Defective translocation of RB1 mutants to the nucleus
  • Replication of the SARS-CoV-1 genome
  • Aberrant regulation of mitotic exit in cancer due to RB1 defects
  • Replication of the SARS-CoV-2 genome
  • Insulin human
  • Insulin pork
  • Bladder cancer
  • Small cell lung cancer
  • Glioma
  • Osteosarcoma
  • Breast cancer
  • Esophageal cancer
  • Hepatocellular carcinoma
  • Chronic myeloid leukemia (CML)
CCND1 cyclin D1
  • SCF(Skp2)-mediated degradation of p27/p21
  • Pre-NOTCH Transcription and Translation
  • RMTs methylate histone arginines
  • Interleukin-4 and Interleukin-13 signaling
  • Cyclin D associated events in G1
  • Ubiquitin-dependent degradation of Cyclin D
  • Ubiquitin-dependent degradation of Cyclin D
  • PTK6 Regulates Cell Cycle
  • Transcriptional Regulation by VENTX
  • Transcriptional regulation by RUNX2
  • Regulation of RUNX1 Expression and Activity
  • RUNX3 regulates WNT signaling
  • RUNX3 regulates p14-ARF
  • Estrogen-dependent gene expression
  • Estrogen-dependent nuclear events downstream of ESR-membrane signaling
  • Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)
  • Acetylsalicylic acid
  • Arsenic trioxide
  • Encorafenib
  • Bryostatin 1
  • Hairy-cell leukemia
  • von Hippel-Lindau syndrome
  • Esophageal cancer
  • Oral cancer
  • Multiple myeloma
  • Laryngeal cancer
  • Breast cancer
CTNNB1 catenin beta 1
  • Degradation of beta-catenin by the destruction complex
  • Beta-catenin phosphorylation cascade
  • TCF dependent signaling in response to WNT
  • Formation of the beta-catenin:TCF transactivating complex
  • Formation of the beta-catenin:TCF transactivating complex
  • LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
  • Apoptotic cleavage of cell adhesion proteins
  • Deactivation of the beta-catenin transactivating complex
  • Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)
  • Ca2+ pathway
  • Adherens junctions interactions
  • Binding of TCF/LEF:CTNNB1 to target gene promoters
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • VEGFR2 mediated vascular permeability
  • Myogenesis
  • Myogenesis
  • Signaling by GSK3beta mutants
  • S33 mutants of beta-catenin aren't phosphorylated
  • S37 mutants of beta-catenin aren't phosphorylated
  • S45 mutants of beta-catenin aren't phosphorylated
  • T41 mutants of beta-catenin aren't phosphorylated
  • RHO GTPases activate IQGAPs
  • Transcriptional Regulation by VENTX
  • InlA-mediated entry of Listeria monocytogenes into host cells
  • RUNX3 regulates WNT signaling
  • Urea
  • Gastric cancer
  • Colorectal cancer
  • Endometrial Cancer
  • Pilomatricoma; Epithelioma calcificans of Malherbe
  • Thyroid cancer
  • Hepatocellular carcinoma
MDM2 MDM2 proto-oncogene
  • AKT phosphorylates targets in the cytosol
  • Oxidative Stress Induced Senescence
  • Oncogene Induced Senescence
  • SUMOylation of transcription factors
  • SUMOylation of ubiquitinylation proteins
  • Trafficking of AMPA receptors
  • Constitutive Signaling by AKT1 E17K in Cancer
  • Ub-specific processing proteases
  • Regulation of TP53 Activity through Phosphorylation
  • Regulation of TP53 Degradation
  • Regulation of TP53 Activity through Methylation
  • Stabilization of p53
  • Regulation of RUNX3 expression and activity
  • Zinc
  • Cis-[4,5-Bis-(4-Bromophenyl)-2-(2-Ethoxy-4-Methoxyphenyl)-4,5-Dihydroimidazol-1-Yl]-[4-(2-Hydroxyethyl)Piperazin-1-Yl]Methanone
  • Cis-[4,5-Bis-(4-Chlorophenyl)-2-(2-Isopropoxy-4-Methoxyphenyl)-4,5-Dihyd Roimidazol-1-Yl]-Piperazin-1-Yl-Methanone
  • Zinc acetate
  • Zinc chloride
  • Zinc sulfate, unspecified form
  • Choriocarcinoma
  • Osteosarcoma
  • Glioma
  • Penile cancer
  • Alveolar rhabdomyosarcoma
FLNA filamin A
  • Platelet degranulation
  • GP1b-IX-V activation signalling
  • Cell-extracellular matrix interactions
  • RHO GTPases activate PAKs
  • OAS antiviral response
  • Artenimol
  • Syndromic X-linked mental retardation with epilepsy or seizures, including: West syndrome (WS); Partington syndrome (PRTS); Proud syndrome (ACCAG); XMR and epilepsy (XMRE); MRXHF1; XMR OPHN1-related (MRXSO) ; XELBD; XMR, Christianson type (MRXSC); Creatine deficiency syndrome (XL-CDS); Renpenning syndrome (RENS1); Epilepsy and mental retardation limited to females (EFMR); Periventricular nodular heterotopia (PVNH); Hydrocephalus (XLH); XMR, JARID1C related (MRXSJ); Boerjeson-Forssman syndrome (BFLS); CK syndrome (CKS)
  • Fronto-Otopalatodigital Osteodysplasia, including: Otopalatodigital syndrome, type I; Otopalatodigital syndrome, type II; Melnick-Needles syndrome; Frontometaphyseal dysplasia
  • Periventricular nodular heterotopia (PVNH)
  • FG syndrome (FGS); Opitz-Kaveggia syndrome
RUNX1 RUNX family transcription factor 1
  • Pre-NOTCH Transcription and Translation
  • Organic cation transport
  • RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs)
  • RUNX1 regulates estrogen receptor mediated transcription
  • Regulation of RUNX1 Expression and Activity
  • Regulation of RUNX1 Expression and Activity
  • RUNX1 regulates expression of components of tight junctions
  • RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function
  • RUNX1 regulates transcription of genes involved in differentiation of HSCs
  • RUNX1 regulates transcription of genes involved in differentiation of HSCs
  • RUNX1 regulates transcription of genes involved in differentiation of keratinocytes
  • RUNX1 regulates transcription of genes involved in differentiation of keratinocytes
  • RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known
  • RUNX1 regulates transcription of genes involved in BCR signaling
  • RUNX1 regulates transcription of genes involved in differentiation of myeloid cells
  • RUNX1 regulates transcription of genes involved in interleukin signaling
  • RUNX1 regulates transcription of genes involved in WNT signaling
  • RUNX2 regulates genes involved in differentiation of myeloid cells
  • RUNX3 regulates p14-ARF
  • Estrogen-dependent gene expression
  • Transcriptional regulation of granulopoiesis
  • Chronic myeloid leukemia (CML)
  • Thrombocytopenia (THC); Familial platelet disorder with associated myeloid malignancy (FPDMM)
  • Acute myeloid leukemia (AML)
  • Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia)
SMAD4 SMAD family member 4
  • Signaling by NODAL
  • Signaling by Activin
  • Signaling by BMP
  • TGF-beta receptor signaling activates SMADs
  • Downregulation of SMAD2/3:SMAD4 transcriptional activity
  • Downregulation of SMAD2/3:SMAD4 transcriptional activity
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • SMAD4 MH2 Domain Mutants in Cancer
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • Transcriptional regulation of pluripotent stem cells
  • Ub-specific processing proteases
  • RUNX2 regulates bone development
  • RUNX3 regulates CDKN1A transcription
  • RUNX3 regulates BCL2L11 (BIM) transcription
  • FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
  • FOXO-mediated transcription of cell cycle genes
  • FOXO-mediated transcription of cell cycle genes
  • Colorectal cancer
  • Hereditary hemorrhagic telangiectasia (HHT)
  • Pancreatic cancer
  • Juvenile polyposis syndrome
DCC DCC netrin 1 receptor
  • Netrin-1 signaling
  • Netrin-1 signaling
  • DSCAM interactions
  • DCC mediated attractive signaling
  • DCC mediated attractive signaling
  • Netrin mediated repulsion signals
  • Caspase activation via Dependence Receptors in the absence of ligand
  • Role of second messengers in netrin-1 signaling
  • Regulation of commissural axon pathfinding by SLIT and ROBO
  • Colorectal cancer
  • Gastric cancer
  • Cancer of the anal canal
VHL von Hippel-Lindau tumor suppressor
  • Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha
  • Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha
  • SUMOylation of ubiquitinylation proteins
  • Neddylation
  • Replication of the SARS-CoV-1 genome
  • Replication of the SARS-CoV-2 genome
  • RHOBTB3 ATPase cycle
  • Antigen processing: Ubiquitination & Proteasome degradation
  • Renal cell carcinoma
  • von Hippel-Lindau syndrome
  • Congenital polycythemia; Familial erythrocytosis (ECYT)
ABL1 ABL proto-oncogene 1, non-receptor tyrosine kinase
  • Regulation of actin dynamics for phagocytic cup formation
  • Role of ABL in ROBO-SLIT signaling
  • Role of ABL in ROBO-SLIT signaling
  • Myogenesis
  • Myogenesis
  • RHO GTPases Activate WASPs and WAVEs
  • HDR through Single Strand Annealing (SSA)
  • Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
  • Cyclin D associated events in G1
  • RUNX1 regulates transcription of genes involved in differentiation of HSCs
  • RUNX2 regulates osteoblast differentiation
  • FCGR3A-mediated phagocytosis
  • Factors involved in megakaryocyte development and platelet production
  • ATP
  • Imatinib
  • Dasatinib
  • N-[4-Methyl-3-[[4-(3-Pyridinyl)-2-Pyrimidinyl]Amino]Phenyl]-3-Pyridinecarboxamide
  • Nilotinib
  • XL228
  • Bosutinib
  • 2-{[(6-OXO-1,6-DIHYDROPYRIDIN-3-YL)METHYL]AMINO}-N-[4-PROPYL-3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE
  • 1-[4-(PYRIDIN-4-YLOXY)PHENYL]-3-[3-(TRIFLUOROMETHYL)PHENYL]UREA
  • Myristic acid
  • PD-166326
  • 5-[3-(2-METHOXYPHENYL)-1H-PYRROLO[2,3-B]PYRIDIN-5-YL]-N,N-DIMETHYLPYRIDINE-3-CARBOXAMIDE
  • 2-amino-5-[3-(1-ethyl-1H-pyrazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,N-dimethylbenzamide
  • Regorafenib
  • Ponatinib
  • Fostamatinib
  • Brigatinib
  • Radotinib
  • Chronic myeloid leukemia (CML)
  • Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia)
BRCA1 BRCA1 DNA repair associated
  • Meiotic synapsis
  • SUMOylation of DNA damage response and repair proteins
  • HDR through Single Strand Annealing (SSA)
  • HDR through Homologous Recombination (HRR)
  • Metalloprotease DUBs
  • Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)
  • Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
  • Resolution of D-loop Structures through Holliday Junction Intermediates
  • Nonhomologous End-Joining (NHEJ)
  • Homologous DNA Pairing and Strand Exchange
  • Processing of DNA double-strand break ends
  • Presynaptic phase of homologous DNA pairing and strand exchange
  • TP53 Regulates Transcription of DNA Repair Genes
  • Regulation of TP53 Activity through Phosphorylation
  • G2/M DNA damage checkpoint
  • Transcriptional Regulation by E2F6
  • Meiotic recombination
  • Defective DNA double strand break response due to BRCA1 loss of function
  • Defective DNA double strand break response due to BARD1 loss of function
  • Breast cancer
  • Ovarian cancer
BTK Bruton tyrosine kinase
  • ER-Phagosome pathway
  • MyD88:MAL(TIRAP) cascade initiated on plasma membrane
  • Regulation of actin dynamics for phagocytic cup formation
  • DAP12 signaling
  • FCERI mediated Ca+2 mobilization
  • FCERI mediated Ca+2 mobilization
  • G alpha (q) signalling events
  • G alpha (12/13) signalling events
  • MyD88 deficiency (TLR2/4)
  • IRAK4 deficiency (TLR2/4)
  • RHO GTPases Activate WASPs and WAVEs
  • G beta:gamma signalling through BTK
  • FCGR3A-mediated phagocytosis
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Dasatinib
  • Inositol 1,3,4,5-Tetrakisphosphate
  • XL418
  • Ibrutinib
  • Acalabrutinib
  • Fostamatinib
  • Zanubrutinib
  • Abivertinib
  • Agammaglobulinemias, including the following six diseases: X-linked agammaglobulinemia (Bruton's agammaglobulinemia, XLA); IgM heavy chain gene deletions; Ig-alpha defect; Autosomal recessive agammaglobulinaemia; B cell-linker protein (BLNK) deficiency; Leucine-rich repeat-containing 8
  • Pituitary Dwarfism (PD); Isolated growth hormone deficiency (IGHD); Short Stature and Pituitary Defects (SSPD); Insulin-like growth factor 1 deficiency (IGFD)
CCNE1 cyclin E1
  • G0 and Early G1
  • SCF(Skp2)-mediated degradation of p27/p21
  • DNA Damage/Telomere Stress Induced Senescence
  • Association of TriC/CCT with target proteins during biosynthesis
  • TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest
  • CDK-mediated phosphorylation and removal of Cdc6
  • Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes
  • Cyclin E associated events during G1/S transition
  • G1/S-Specific Transcription
  • Cyclin D associated events in G1
  • p53-Dependent G1 DNA Damage Response
  • PTK6 Regulates Cell Cycle
  • Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)
  • RHOBTB3 ATPase cycle
  • Laryngeal cancer
  • Gastric cancer
GSN gelsolin
  • Caspase-mediated cleavage of cytoskeletal proteins
  • Neutrophil degranulation
  • Amyloid fiber formation
  • Zinc
  • Latrunculin A
  • Copper
  • Zinc acetate
  • Lattice corneal dystrophies (LCD), including: Biber-Haab-Dimmer dystrophy; Familial amyloid polyneuropathy type IV; Meretoja syndrome
  • Familial amyloidosis
NR0B1 nuclear receptor subfamily 0 group B member 1
  • Dexamethasone
  • Dexamethasone acetate
  • Glycerol kinase deficiency (GKD), including: Hyperglycerolemia; Chromosome Xp21 deletion syndrome; Adrenal hypoplasia, congenital (AHC); Duchenne muscular dystrophy (DMD)
  • 46,XY disorders of sex development (Disorders of gonadal development), including: Gonadal agenesis; Complete and partial gonadal dysgenesis; Testis regression; Ovotesticular DSD
NR3C2 nuclear receptor subfamily 3 group C member 2
  • HSP90 chaperone cycle for steroid hormone receptors (SHR)
  • SUMOylation of intracellular receptors
  • Nimodipine
  • Progesterone
  • Spironolactone
  • Fluticasone propionate
  • Testosterone
  • Fludrocortisone
  • Eplerenone
  • Clobetasol propionate
  • Felodipine
  • Desoxycorticosterone pivalate
  • Drospirenone
  • Stanolone
  • Metribolone
  • Aldosterone
  • Corticosterone
  • Desoxycorticosterone acetate
  • Fluticasone furoate
  • Fluticasone
  • Testosterone cypionate
  • Testosterone enanthate
  • Testosterone undecanoate
  • Stanolone acetate
  • Hyperkalemic distal renal tubular acidosis (RTA type 4), including the following two diseases: Pseudohypoaldosteronism type I (PHA1); Pseudohypoaldosteronism type II (Gordon's syndrome)
  • Hypertension exacerbated in pregnancy
NR5A1 nuclear receptor subfamily 5 group A member 1
  • Nuclear Receptor transcription pathway
  • SUMOylation of intracellular receptors
  • Transcriptional regulation of pluripotent stem cells
  • Transcriptional regulation of testis differentiation
  • (2R)-3-{[{[(2S)-2,3-DIHYDROXYPROPYL]OXY}(HYDROXY)PHOSPHORYL]OXY}-2-[(9E)-HEXADEC-9-ENOYLOXY]PROPYL (9E)-OCTADEC-9-ENOATE
  • Phosphatidyl ethanol
  • Premature ovarian failure
  • 46,XY disorders of sex development (Disorders of gonadal development), including: Gonadal agenesis; Complete and partial gonadal dysgenesis; Testis regression; Ovotesticular DSD
NSD1 nuclear receptor binding SET domain protein 1
  • PKMTs methylate histone lysines
  • Beckwith-Wiedemann syndrome
  • Sotos syndrome and Weaver syndrome

Page 1 out of 14 pages